Am Fam Physician. 2006 Jan 15;73(2):330-333.
Drug treatment of osteoporosis, defined by the World Health Organization as bone mineral density greater than 2.5 standard deviations less than the young healthy mean, has been proven to prevent fractures. It is less clear, however, whether physicians should treat osteopenia (femoral-neck T-score of −1.6 to −2.5) in post-menopausal women who do not have a history of fractures. This is because there is a high prevalence of osteopenia in these patients and the drugs are expensive. The National Osteoporosis Foundation and the American College of Obstetrics and Gynecology recommend drug therapy for fracture prevention in women with T-score thresholds of −2.0 or less if no additional fractures are present and −1.6 or less if one or more additional fractures are present. Schousboe and colleagues performed a cost-effectiveness analysis to estimate the cost per quality-adjusted life-year (QALY) gained from a five-year alendronate (Fosamax) regimen in women 55 to 75 years of age with osteopenia and no additional risk factors.
Primary data sources for the analysis were the Fracture Intervention Trial, which evaluated the effectiveness of alendronate versus placebo in women without preexisting vertebral fractures; studies of age-specific fracture rates; acute and long-term medical costs associated with hip and vertebral fractures; estimated costs associated with missed days of work; and calculations of disutility related to each type of fracture. The participants were divided into eight health states based on the presence, location, and presentation (i.e., clinically evident at onset or identified later on incidental radiography) of fractures. The yearly cost of alendronate was set at $842, the average wholesale price in 2001. Other assumptions included a 100 percent adherence rate and trivial medical costs from side effects.
The calculated cost per QALY gained from alendronate treatment ranged from $70,732 for a 65-year-old woman with a nearly osteoporotic T-score of −2.4 to $332,250 for a 75-year-old woman with a nearly normal T-score of −1.5. The cost per QALY increased with age and decreased with more negative T-scores. At a T-score threshold of −1.5, even a 55-year-old woman only benefited from alendronate therapy at a cost of more than $250,000 per QALY.
Citing a commonly used societal cost-effectiveness threshold of $50,000 per QALY gained, the authors conclude that alendronate therapy is not a cost-effective means to prevent fractures in postmenopausal women with osteopenia and no other risk factors.
Schousboe JT, et al. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med. May 3, 2005;142:734–41.
editor’s note: When combined with recent data from a Fracture Intervention Trial subgroup that had femoral-neck T-scores between −1.6 and −2.5,1 Schousboe and colleagues’ analysis should help organizations make recommendations about preventive therapies for women with osteopenia. Drug therapies should be clinically beneficial and consume no more than a reasonable proportion of societal resources. Although Quandt and colleagues1 have found that alendronate therapy in women with osteopenia reduces vertebral fracture risk, Schousboe’s analysis suggests that it costs more than a reasonable amount. Additionally, any cost-effectiveness gained from future generic versions is likely offset by the improbable assumptions of perfect drug adherence and no costs from gastrointestinal side effects. An editorial2 calls on physicians to base decisions regarding drug therapy on an overall assessment of fracture risk rather than on T-scores alone. For lower-risk patients, physicians can still provide primary prevention by encouraging adequate calcium intake, vitamin D supplements, and weight-bearing exercise.—k.w.l.
1. Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of −1.6 to −2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc. March 2005;80:343–9.
2. McClung MR. Osteopenia: to treat or not to treat? Ann Intern Med. May 3, 2005;142:796–7.
Copyright © 2006 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions